Navigation Links
BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
Date:5/3/2011

NOVATO, Calif., May 3, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tuesday, May 10, 2011 at 2:20 p.m. PT.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Announces First Quarter 2011 Financial Results
2. BioMarin to Present at the Deutsche Bank Healthcare Conference
3. BioMarin to Present at the Barclays Global Healthcare Conference
4. BioMarin to Present at the Cowen Health Care Conference
5. BioMarin to Present at the Citi Global Healthcare Conference
6. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
7. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
8. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
9. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
10. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
11. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... -- According to a new market research report "Gynecology ... (Laparoscopy, Colposcopy, Hysteroscopy, D&C, Ablation, Biopsy), & End User (Hospital, Clinic, ... the global market is expected to reach USD 2.44 Billion by ... 7.1% during the forecast period. Continue ... ...
(Date:2/22/2017)... PUNE, India , February 22, 2017 ... titled, "Automated Radio Synthesis Modules Market: Global Opportunity Analysis and ... market was worth $20 million in 2015 and projected to ... 6.6% from 2016 to 2022. North America ... market revenues and unit volumes, whereas Asia-Pacific ...
(Date:2/22/2017)... Conn. , Feb. 22, 2017   Protein ... maker of Flublok® Influenza Vaccine , announced today ... Partnership for Influenza Vaccine Introduction (PIVI) and the Mongolian ... devastating impacts of the flu.  The doses of Flublok ... Mongolia for health care workers, ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... , ... ANGLESTRONG , the new recovery management app with multiple innovative ... Store and Google Play . Florida-based Sober Network, Inc., the premier provider ... with Angle to build ANGLESTRONG. The new recovery management app is a passion project ...
(Date:2/22/2017)... ... February 22, 2017 , ... Bellus Medical, a leader in ... the delivery of Platelet Rich Plasma (PRP). PRP systems are used by physicians ... tissue synthesis and provide a faster and more efficient healing process. There are ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... and 72 percent of those report that family members or friends have also ... they suffer from hearing loss wear hearing aids. One reason, suggested by 89 ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the ... of dogs, according to the Association for Pet Obesity Prevention (APOP). During the ninth ... food issues such as the benefits of corn and grains, value of raw and ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... BrightStar ... several sponsors of the Medical University of South Carolina (MUSC) Center on Aging’s ... Pleasant, SC. “MUSC’s Center on Aging is a tremendous resource in our community. We ...
Breaking Medicine News(10 mins):